[1]王慧睿,郭淑利,李　波,等.伊马替尼治疗后慢性粒细胞白血病患者BCR-ABL酪氨酸激酶区突变特征分析[J].新乡医学院学报,2017,34(6):489-492.[doi:10.7683/xxyxyxb.2017.06.009]
　WANG Hui-rui,GUO Shu-li,LI Bo,et al.Characteristics of BCR-ABL tyrosine kinase domain point mutations in imatinib treated chronic myeloid leukemia patients[J].Journal of Xinxiang Medical University,2017,34(6):489-492.[doi:10.7683/xxyxyxb.2017.06.009]
点击复制

伊马替尼治疗后慢性粒细胞白血病患者BCR-ABL酪氨酸激酶区突变特征分析
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
34
期数:
2017年6
页码:
489-492
栏目:
临床研究
出版日期:
2017-06-05

文章信息/Info

Title:
Characteristics of BCR-ABL tyrosine kinase domain point mutations in imatinib treated chronic myeloid leukemia patients
作者:
王慧睿; 郭淑利; 李　波; 王万里; 王松云; 肖蓬莉; 田红旗
（郑州大学附属洛阳中心医院血液内科，河南　洛阳　471009）
Author(s):
WANG Hui-rui; GUO Shu-li; LI Bo; WANG Wan-li; WANG Song-yun; XIAO Peng-li; TIAN Hong-qi
（Department of Hematology，Luoyang Central Hospital Affiliated to Zhengzhou University，Luoyang 471009，Henan Province，China）
关键词:
伊马替尼; 慢性粒细胞白血病; 酪氨酸激酶区; 点突变
Keywords:
imatinib; chronic myeloid leukemia; tyrosine kinase; point mutation
分类号:
R733.72
DOI:
10.7683/xxyxyxb.2017.06.009
文献标志码:
A
摘要:
目的　研究伊马替尼治疗的慢性粒细胞白血病（CML）患者BCR-ABL酪氨酸激酶区点突变发生情况。方法　对伊马替尼治疗的30例CML患者的37份骨髓标本采用巢式反转录-聚合酶链式反应进行反转录、扩增、测序；应用GeneBank进行序列同源性比较，分析BCR-ABL酪氨酸激酶区点突变发生情况，并分析其与伊马替尼耐药的关系。结果　30例患者检出突变10例，阳性率33.3%。10例突变患者共检出9种点突变，分别为T315I 2例、 E255K 1例、D276G +F317L 1例、F317L 2例、Y253H+M244V 1例、F359V 1例、H396R 1例、E279K 1例。CML-加速/急变期（AP/BP）、CML-慢性期（CP）患者的突变检出率分别为38.5%（5/13）和29.4%（5/17），CML-AP/BP患者突变检出率与CML-CP患者比较差异无统计学意义（χ2=1.258，P>0.05）；10例点突变患者中7例检出点突变时疾病进展至AP/BP，3例患者检出点突变时仍处于CP；AP/BP患者检出点突变的中位时间为6个月，明显早于CP患者的20个月 （χ2=9.103,P<0.05）。结论　BCR-ABL酪氨酸激酶区点突变是伊马替尼治疗CML失败的主要原因之一，定期监测BCR-ABL酪氨酸激酶区突变有助于酪氨酸激酶抑制剂疗效的评估和治疗方案的调整。
Abstract:
Objective　To explore the BCR-ABL tyrosine kinase domain point mutations in imatinib treated chronic myeloid leukemia（CML） patients.Methods　Totally 37 bone samples from 30 CML patients were included in this study.All samples were reversely transcribed，amplified and sequenced by nested reverse transcription-polymerase chain reaction （RT-PCR）；then the sequence homology was analysed by GeneBank.The occurrence of BCR-ABL tyrosine kinase domain point mutations was analysed and its relationship with imatinib resistance was analyzed.Results　In the 30 patients，mutations in BCR-ABL kinase domain were detected in 10 patients（33.3%）.Nine types of mutations were detected，including T315I in two patients，E255K in one patient，D276G and F317L in one patient，F317L in two patients，Y253H and M244V in one patient，F359V in one patient，H396R in one patient，E279K in one patient.The mutation rate of patients with CML in the stage of accelerated-phase/blast-phase （AP/BP） and chronic-phase （CP） was 38.5% （5/13） and 29.4%（5/17） respectively，and there was no significant difference in the mutation rate between the two phase（χ2=1.258，P>0.05）.In the ten patients，seven patients progressed to AP/BP when the mutation was detected，another three patients were still at CP.The median time of detection of mutation was 6 months in patients at the stage of AP/BP，which was significantly earlier than that in the patients at the stage of CP（20 months）（χ2=9.103，P<0.05）.Conclusion　BCR-ABL kinase domain mutation is one of the main reasons of imatinib resistance.Regular monitoring of BCR-ABL tyrosine kinase domain mutation is helpful in assessing the efficacy of tyrosine kinase inhibitors （TKI） in treatment of CML and adjusting the therapeutic regimens.

参考文献/References:

［1］　ROWLEY J D.Letter：a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining［J］.Nature，1973，243（5405）：290-293.
［2］　GROFFEN J，STEPHENSON J R，HEISTERKAMP N，et al.Philadelphia chromosomal breakpoints are clustered within a limited region，bcr，on chromosome 22［J］.Cell，1984，36（1）：93-99.
［3］　DRUKER B J.Translation of the Philadelphia chromosome into therapy for CML［J］.Blood，2008，112（13）：4808-4817.
［4］　SHARMA P，MOHANTY S，KOCHUPILLAI V，et al.Mutations in ABL kinase domain are associated with inferior progression-free survival［J］.Leuk Lymphoma，2010，51（6）：1072-1078.
［5］　SOVERINI S，DE BENEDITTIS C，PAPAYANNIDIS C，et al.Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era：the main changes are in the type of mutations，but not in the frequency of mutation involvement［J］.Cancer，2014，120（7）：1002-1009.
［6］　张之南.血液病诊断及疗效标准［M］.北京：科学出版社，2007：911-917.
［7］　朱平，夏君燕，刘红星，等.我国210例伊马替尼耐药慢性髓细胞白血病和Ph阳性急性淋巴细胞白血病ABL1基因突变特征［J］.中华检验医学杂志，2012，35（1）：17-22.
［8］　QIN Y Z，CHEN S S，JIANG B，et al.Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients［J］.Ann Hematol，2011，90（1）：47-52.
［9］　KIM S H，KIM D，KIM D W，et al.Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients：poor clinical outcome of P-loop and T315I mutation is disease phase dependent［J］.Hematol Oncol，2009，27（4）：190-197.
［10］　SOVERINI S，COLAROSSI S，GNANI A，et al.Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients：by the GIMEMA Working Party on Chronic Myeloid Leukemia［J］.Clin Cancer Res，2006，12（24）：7374-7379.
［11］　ELIAS M H，BABA A A，AZLAN H，et al.BCR-ABL kinase domain mutations，including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-frequency and clinical outcome［J］.Leuk Res，2014，38（4）：454-459.
［12］　BENGIO R M，RIVA M E，MOIRAGHI B，et al.Clinical outcome of chronic myeloid leukemia imatinib-resistant patients：do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study［J］.Leuk Lymphoma，2011，52（9）：1720-1726.
［13］　WEISBERG E，MANLEY P W，BREITENSTEIN W，et al.Characterization of AMN107，a selective inhibitor of native and mutant Bcr-Abl［J］.Cancer Cell，2005，7（2）：129-141.
［14］　REDAELLI S，PIAZZA R，ROSTAGNO R，et al.Activity of bosutinib，dasatinib，and nilotinib against 18 imatinib-resistant BCR/ABL mutants［J］.J Clin Oncol，2009，27（3）：469-471.

相似文献/References:

[1]潘静夫,李素霞,宋传莲,等.小剂量靛玉红为主治疗慢性粒细胞白血病[J].新乡医学院学报,1992,9(02):127.
[2]王慧睿,郭淑利,李　波,等.伊马替尼和达沙替尼治疗初发慢性粒细胞白血病慢性期患者疗效观察[J].新乡医学院学报,2018,35(6):495.[doi:10.7683/xxyxyxb.2018.06.011]
　WANG Hui-rui,GUO Shu-li,LI Bo,et al.Comparison of the efficacy of imatinib and dasatinib for treatment of newly diagnosed chronic myelogenous leukemia chronic phase patients[J].Journal of Xinxiang Medical University,2018,35(6):495.[doi:10.7683/xxyxyxb.2018.06.011]

更新日期/Last Update: 2017-06-05